An implication of this is that irrespectively of whether different ways of targeting the spliceosome have anti-tumour activity through divergent downstream mechanisms c-MYC could act as a common sensitizer by increasing the extent of alterations in splicing. The gene discussed is MYC; the disease is neoplasm.